| Title | Current data on propionibacterium acnes and its involvement on acne vulgaris pathogenicity | |
| Authors | Anthony M. Kyriakopoulos and Ioanna Grech
Department of Aesthetics and Cosmetology, School for Professions of Health and Welfare, Technological Education Institution of Athens, Egaleo, Athens, Greece |
|
| Citation | Kyriakopoulos, A.M., Grech, I.: Current data on propionibacterium acnes and its involvement on acne vulgaris pathogenicity, Epitheorese Klin. Farmakol. Farmakokinet. 25(2): 75-82 (2011) | |
| Publication Date | Accepted for publication (Final version): July 1, 2011 | |
| Full Text Language | English | |
| Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)
pharmakonpress[at]pharmakonpress[.]gr |
|
| Keywords | Propionibacteium acnes, acne vulgaris pathogenicity, delayed hypersensitivity response, microbial duct overpopulation, microbial resistance to antibiotic and isotretinoin treatments. | |
| Other Terms | review article | |
| Summary | Propionibacterium acnes is the most frequent commensal of the human skin. The implication of this bacterium to the pathogenesis of acne is well established. Although a common habitat of the skin with mutualistic properties, in most cases, in the actual pathogenesis of acne, there is a direct link of bacterial load within the pilosebaceous gland and the severity of disease. It is recognized that the distinction between a harmless flora and a pathogenic agent often lies on the skin’s capacity to resist infection and not to the inherent properties of the microbe. Is has been proved that P. acnes overpopulation within the acne lesions leads to a type 4 delayed hypersensitivity response where neutrophil chemotaxis protagonist. Furthermore, be-sides the immune response of the host a direct effect of P. acnes on keratinocytes initiate the inflammatory process with the release of certain cytokines (IL1α, IL 1β, GM-CSF, TNF-α). Bearing in mind the ever in-creasing resistance of P. acnes to antibiotic treatments and the long standing relapse rate, up to 48%, to isotretinoin treatments it is important to manage acne as an inflammatory disorder and focus on treatments with other medicinal formulations that modulate the disturbed immune reaction due to duct microbial overpopulation. | |
| References | 1. Ashkenazi H., Malik Z., Harth Y., et al.: Eradication of Propionibacterium acnes by its endogenous porphyrins after illumination with high density blue light. FEMS Immunol Med Microbiol. 35: 17-24 (2003)
2. Holland K., Aldana O., Bojar R., et al.: Propionibacterium acnes and acne. Dermatology 196: 67-68 (1998) 3. Strauss J.: Sebaceous gland, acne and related disorders – An epilogue. Dermatology 196: 182-184 (1998) 4. Cogen A., Nizet V., Gallo R.: Skin microbiota: A source of disease or defense? Br. J. Dermatol. 158: 442-455 (2008) 5. Fujimura S., Nakamura T.: Purification and properties of a bacteriocin-like substance (Acnecin) of oral propionibacterium acnes. Antimicrob. Agents Chemoth. 14: 893-898 (1978) 6. Jakab E., Zbinden R., Gubler J., et al.: Severe infections caused by Propionibacterium acnes: an underestimated pathogen in late postoperative infections. Yale J. Biol. Med. 69: 477-482 (1996) 7. Kotilainen P., Merilati-Palo R., Lehtonen O.P., et al.: Propionibacterium acnes isolated from sterna osteitis in a patient with SAPHO syndrome. J. Rheumatol. 23: 1302-1304 (1996) 8. Gao Z., Tseng C., Pei Z., Blaser M.: Molecular analysis of human forearm superficial skin bacterial biota. Proc. Natl. Acad. Sci. 104: 2927-2932 (2007) 9. Webster G.: Inflammatory acne represents hypersensitivity to Propionibacterium acnes. Dermatology 196: 80-81 (1998) 10. Akamatsu H., Horio T.: The possible role of reactive oxygen species generated by neutrophils in mediating acne inflammation. Dermatology 196: 82-85 (1998) 11. Webster G., Leyden J., Nilson R.: Complement activation in acne vulgaris: Consumption of complement by comedones. Infect. Immun. 21: 183-186 (1979) 12. Toyoda M., Norohashi M.: New aspects in acne inflamemation. Dermatology 206:17-23 (2003) 13. Zouboulis Ch.C., Bohm M.: Neuroendocrine regulation of sebocytes a pathogenetic link between stress and acne. Exp. Dermatol. 13(Suppl. 4): 31-35 (2004) 14. Gaputo G., Archer G., Calderwood S., et al.: Native valve endocarditis due to coagulase-negative staphylococci. Clinical and microbiologic features. Am. J. Med. 83: 619-625 (1987) 15. Overturf G., Sherman M., et al.: Neonatal necrotizing enderocolitis associated with delta toxin producing methicillin-resistant Staphylococcus aureus. Pediatr. Infect. Dis. J. 9: 88-91 (1990) 16. Sahl H.: Staphylococcin 1580 is identical to the lantinbiotic epidermin: implications for the nature of bacteriocins from gram positive bacteria. Appl. Environ. Microbiol. 60: 752-755 (1994) 17. Thomsen M., Lomholt H., Kilian M.: Acne is not associated with yet-uncultured bacteria. J. Clin. Microbiol. 46: 3355-3360 18. Stein R., Lebwohn M.: Acne Therapy: Clinical pearls. Sem. Cut. Med. Surg 20: 184-189 (2001) 19. Poshi P.: Acne: Androgens and Microbiology. Drug Develop. Res. 13: 157-168 (1988) 20. Brugemann H., Henne A., Hoster F., et al.: The complete genome sequence of Propionibacterium acnes, a commensal of human skin. Science 305: 671-673 (2004) 21. Bataille V., Sneider H., MacGregor A.J., et al.: The influence of genetics and environmental factors in the pathogenesis of acne: a twin study of acne in women. J. Invest. Dermatol. 119: 1317-1322 (2002) 22. Sedgwick J., Bergstresser P., Hurd E.: Increased superoxide generation by normal granulocytes incubated in sera from patients with psoriasis. J. Invest. Dermatol. 76: 158-163 (1981) 23. Kim J.: Review of the innate response in acne vulgaris: activation of the Toll-like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology 211: 193-198 (2005) 24. Jugeau S., Tenaud I., Knol A., et al.: Induction of Toll-like receptors by Propionibacterium acnes. Br. J. Dermatol. 153: 1005-1013 (2005) 25. Vowels B., Yang S., Leyden J.: Induction of pro-inflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect. Immun. 63: 3158-3165 (1995) 26. Nagy I., Pivarcsi A., Koreck A., et al.: Distinct strains of Propionibacterium acnes. Induce selective human beta-defensin-2 and interleukin-8 expression in human keratinocytes through toll-like receptors. J. Invest. Dermatol. 124: 931-938 (2005) 27. Kaplan G., Witmer M., Nath I., et al.: Influence of delayed immune reactions on human epidermal keratinocytes. Proc. Natl. Acad. Sci. 83: 3469-3473 (1986) 28. Poulter L.W., Seymour G.J., Duke O., Janossy G., Panayi G.: Immunohistological analysis of delayed-type hypersensitivity in man. Cell Immunol. 74: 358-369 (1982) 29. Niwa Y., Miyake S., Sakate T., et al.: Auto-oxidative damage in Bahcet’s disease-endothelial cell damage following the elevated oxygen radicals generated by stimulated neutrophils. Clin. Exp. Immunol. 49: 247-255 (1982) 30. Hazen S., Hsu F., d’Avignon A., et al.: Human neutrophiles employ myeloperoxidase to convert alpha-amino-acids to a battery of reactive aldehydes: a pathway for aldehyde generation at sites of inflammation. Biochemistry 37: 6864-6873 (1998) 31. Kurutas E., Arican O., Sasmaz S.: Superoxide dismutase and myeloperoxidase activities in polymorphonuclear leukocytes in acne vulgaris. Acta Dermatovenerol. Alp. Pannonica Adriat. 14(2): 39-42 (2005) 32. Paraskevaidis A., Drakoulis N., Roots I., et al.: Poly-morphisms in the human cytocrome P-450 1A1 Gene (CYP1A1) as afator for developing acne. Dermatology 196: 171-175 (1998) 33. Eady E.: Bacterial resistance in acne. Dermatology 196: 59-66 (1998) 34. Deno B.: Topical antibacterial therapy for acne vulgaris. Drugs 64: 2389-2397 (2004) 35. Eady A., Cove J., Layton A.: Is antibiotic resistance in cutaneous propionibacteria clinically relevant? Implications of resistance for acne patients and prescribers. Am. J. Dermatol. 12: 813-831 (2003) 36. Patel M., Bowe W., Heugebaert C., Shalita A.: The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: a review. J. Drugs Dermatol. 9: 655-664 (2010) 37. Kinney M., Yentzer B., Fleisher A., et al.: Trends in the treatment of acne vulgaris: are measures being taken to avoid antimicrobial resistance? J. Drugs Dermatol. 9: 519-524 (2010) 38. Connell K., Wilkin J., Pitts M., et al.: Isotretinoin (Accutane) and serious phychiatric adverse events. J. Am. Acad. Dermatol. 48: 306-307 (2002) 39. Lehucher-Ceyrac D., de la Salmoniere P., Chastang C., et al.: Predictive factors for failure of isotretinoin treatment in acne patients: results from a cohort of 237 patients. Dermatology 198: 278-283 (1999) 40. Azoulay L., Oraichi D., Berard A.: Isotretinoin therapy and the incidence of acne relapse: a nested case-control study. Br J. Derm. 157: 1240-1248 (2007) 41. Harms M., Masouye B., Rabeff B.: The ralapses of cystic acne after isotretinoin treatment are age related: A long term follow-up study. Dermatologica 172: 148-153 (1986) |
|
| Relative Papers |
Online ISSN 1011-6575